BD To Host Virtual 2026 Annual Meeting of Shareholders
Rhea-AI Summary
BD (NYSE: BDX) will host a virtual 2026 Annual Meeting of Shareholders on Tuesday, January 27, 2026 at 1:00 p.m. ET. Shareholders of record as of the close of business on December 8, 2025, or their duly authorized proxies, can attend, participate, vote, and ask questions by visiting https://meetnow.global/MFT7Y46. Guests may join in listen-only mode without a control number. A replay of the webcast will be available shortly after the meeting at investors.bd.com for approximately one year from the meeting date.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BDX declined 0.60%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BDX was down 1.18% pre-news with mixed, mostly small peer moves: ALC -0.27%, RMD -0.18%, WST -0.04%, BAX +0.81%, HOLX +0.09%, and no peers in the momentum scanner, indicating stock-specific trading conditions rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Trial progress update | Positive | +2.1% | Phasix™ prophylactic use milestone and >85% PREVENT trial enrollment. |
| Dec 18 | R&D collaboration | Positive | -0.3% | Immunotherapy collaboration with Penn using high-parameter flow cytometry. |
| Dec 15 | Product certification | Positive | -1.9% | IVDR certification for VIASURE assays expanding BD MAX™ menu in Europe. |
| Dec 04 | Strategic partnership | Positive | +0.1% | ChemoGLO collaboration to expand hazardous drug contamination testing. |
| Dec 03 | Product launch | Positive | +1.6% | New BD FACSDiscover A8 Cell Analyzer configurations for broader lab access. |
Recent operational and collaboration news has more often aligned positively with price, but there are instances where positive updates coincided with mild selloffs.
Over the last months, BD reported multiple product and collaboration milestones. On Dec 3, 2025, it launched new BD FACSDiscover A8 Cell Analyzer configurations, and on Dec 4, 2025, it announced a ChemoGLO partnership on hazardous drug contamination testing. Additional updates covered IVDR-certified VIASURE assays and an immunotherapy-focused collaboration with Penn, plus strong progress in the PREVENT trial and Phasix™ Mesh adoption. Today’s annual meeting logistics notice fits within this cadence of steady corporate communication but is procedural rather than operational.
Market Pulse Summary
This announcement sets logistics for BD’s 2026 virtual Annual Meeting of Shareholders on January 27, 2026, including record date, online access, and a replay available for about one year. In context with recent product launches, collaborations, and trial progress, it continues a steady flow of corporate communication but adds no new financial or clinical metrics. Investors may watch the meeting agenda and any accompanying materials for strategic or capital allocation updates.
AI-generated analysis. Not financial advice.
As described in the proxy materials for the Annual Meeting previously distributed, shareholders as of the close of business on December 8, 2025, or their duly authorized proxies, will be able to attend and participate in the Annual Meeting, vote their shares and ask questions by visiting https://meetnow.global/MFT7Y46. Guests may also access the Annual Meeting but in listen-only mode. No control number is required for guests.
A replay of the webcast will be available shortly after the Annual Meeting on the BD website at investors.bd.com for approximately one year from the date of the Annual Meeting.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media: | Investors: |
Fallon McLoughlin | Adam Reiffe |
Director, Public Relations | Vice President, Investor Relations |
201.258.0361 | 201.847.6927 |
View original content:https://www.prnewswire.com/news-releases/bd-to-host-virtual-2026-annual-meeting-of-shareholders-302658834.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
When will BD (BDX) hold its 2026 Annual Meeting of Shareholders?
Who is eligible to attend and vote at the BD (BDX) 2026 Annual Meeting?
How can eligible BD (BDX) shareholders attend and participate in the virtual meeting?
Can guests view BD's (BDX) 2026 Annual Meeting without voting rights?
Will BD (BDX) provide a replay of the 2026 Annual Meeting webcast?
Where can I find the proxy materials referenced for BD's (BDX) 2026 Annual Meeting?
